Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13927523 | 0.91 | METTL3 (0.48) | METTL3CSF1RRAB9APDE3BPDE3A | |
| SCHEMBL4207612 | 0.91 | METTL3 (0.50) | METTL3CSF1RPDE3BPDE3AEGFR | |
| SCHEMBL15460005 | 0.90 | METTL3 (0.44) | METTL3CSF1RRAB9APDE3BPDE3A | |
| SCHEMBL16380512 | 0.90 | METTL3 (0.48) | METTL3CSF1RPDE3BPDE3AEGFR | |
| SCHEMBL1104891 | 0.90 | METTL3 (0.56) | METTL3CSF1RKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4211289 | 0.89 | METTL3 (0.55) | METTL3CSF1RKDM4EALDH1A1 | |
| SCHEMBL4209881 | 0.89 | METTL3 (0.48) | METTL3CSF1RPDE3BPDE3ALMNA | |
| SCHEMBL1104896 | 0.88 | METTL3 (0.47) | METTL3CSF1RRAB9APDE3BPDE3A | |
| SCHEMBL13927561 | 0.87 | METTL3 (0.48) | METTL3CSF1RPDE3BPDE3AEGFR | |
| SCHEMBL1104880 | 0.85 | METTL3 (0.48) | METTL3CSF1RPDE3BPDE3AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880017-B1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2880017-B1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2880017-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | Gilead Sciences, Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8877931-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877931-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8796459-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8759525-B2 | Process and intermediates for preparing integrase inhibitors | Gilhead Sciences, Inc. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2014022707-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140039194-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039194-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8383819-B2 | Method for producing 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-8324244-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120238758-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8153801-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2010-11-18 | — | — | US | disclosed |
| US-7825252-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885CSF1R 3385/4885RAB9A 3788/4885 |
| US-20140039194-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885CSF1R 3385/4885RAB9A 3788/4885 |
| US-20120238758-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885CSF1R 3385/4885RAB9A 3788/4885 |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885CSF1R 3385/4885RAB9A 3788/4885 |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885CSF1R 3385/4885RAB9A 3788/4885 |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885CSF1R 3385/4885RAB9A 3788/4885 |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | IMPDH1, IMPDH2, CDK20 | METTL3 938/4885CSF1R 3788/4885RAB9A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.